Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.8 USD | -2.86% | +8.45% | -0.44% |
May. 28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
Financials (USD)
Sales 2024 * | 179M | Sales 2025 * | 201M | Capitalization | 297M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | 5M | EV / Sales 2024 * | 1.66 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.48 x |
P/E ratio 2024 * |
-16.5
x | P/E ratio 2025 * |
-512
x | Employees | 427 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.22% |
Latest transcript on AxoGen, Inc.
1 day | -2.86% | ||
1 week | +8.45% | ||
Current month | -0.44% | ||
1 month | +6.08% | ||
3 months | -35.61% | ||
6 months | +3.82% | ||
Current year | -0.44% |
Managers | Title | Age | Since |
---|---|---|---|
Karen Zaderej
CEO | Chief Executive Officer | 62 | 06-04-30 |
Nir Naor
DFI | Director of Finance/CFO | 49 | Dec. 05 |
Marc Began
CMP | Compliance Officer | 57 | 23-03-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Thomas
BRD | Director/Board Member | 68 | 20-09-29 |
Director/Board Member | 63 | 16-08-31 | |
John Johnson
BRD | Director/Board Member | 66 | 21-07-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 6.83 | -2.43% | 180,072 |
24-05-30 | 7 | +4.32% | 516,757 |
24-05-29 | 6.71 | +1.05% | 389,345 |
24-05-28 | 6.64 | +5.90% | 534,518 |
24-05-24 | 6.27 | +2.62% | 235,047 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.44% | 297M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.61B |
- Stock Market
- Equities
- AXGN Stock